



CES Innovative Pharmaceuticals Index

Description	The Index aims to capture the performance of leading pharmaceutical and biotechnology companies that contribute innovative solutions for health care problems, and pursue research in frontier areas of biotechnology.
Index Universe	<ul style="list-style-type: none">Stocks eligible for both “Northbound Trading” and “Southbound Trading” under Stock Connect;Stocks classified into biotechnology or chemical medicine, and actively engaged in anti-tumor drugs, antibiotics, biotechnology research services, cardiovascular drugs, genetic engineering, biological diagnostic or therapeutic products, innovative drugs, or human vaccine.
Selection Criteria	<ul style="list-style-type: none">Exclude securities in the universe whose daily average trading value in the past 1 year is less than 8 million CNY;Rank securities by daily average market cap in the past 1 year and top 30 are selected as the constituents of Index.
No. of stocks	30
Buffer zone	±20%
Calculation Methodology	<ul style="list-style-type: none">Free float-adjusted market cap. weightedEach component's weight is capped at 10%
Review Frequency	Half-yearly
End of Day Index (Currency)	CNY
Base Value	2,000
Base Date	30 December 2011
Dissemination	Once a day, after the close of trading

Note: The index, formerly known as CES Innovative Biotech Index, was renamed to CES Innovative Pharmaceuticals Index.

Contact Us

Suites 906-908, 9/F, Two Exchange Square, 8 Connaught Place, Central, Hong Kong

☎ (852) 2803 8200

☎ (852) 2868 3770

✉ cescinfo@cesc.com

🌐 www.cesc.com

Disclaimer: All information contained herein (the “Information”) is provided for reference only. China Exchanges Services Company Limited (“CESC”) endeavours to ensure the accuracy and reliability of the information but makes no warranty or representation as to its accuracy, completeness, reliability or suitability for any particular purpose. CESC accepts no liability (whether in tort or contract or otherwise) whatsoever to any person for any loss or damage arising from any inaccuracy or omission in the Information and/or from any decision, action or non-action based on or in reliance upon the Information. None of the Information is intended to constitute investment advice and/or a recommendation to make (or refrain from making) any kind of investment decision. Any person intending to use the Information and/or any part thereof should seek independent professional advice. Distribution, redistribution, reproduction, modification, transmission, use, reuse and/or storage of the Information in whole or in part, in any form or by any means are strictly prohibited without the prior written permission of CESC. The Information is provided without warranties of any kind, either expressed or implied, including (but not limited to) warranties of merchantability, merchantable quality, title, fitness for a particular purpose, security and non-infringement. China Securities Index Co, Ltd will make its commercially reasonable endeavours to ensure the accuracy and reliability of the Information provided, but does not guarantee its accuracy and reliability and accepts no liability (whether in tort or in contract or otherwise) for any loss or damage suffered by any person arising from any inaccuracies or omissions and/or for any reliance placed on such Information.